𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hypomethylation of the 14-3-3σ promoter leads to increased expression in non-small cell lung cancer

✍ Scribed by Vijayababu M. Radhakrishnan; Taylor J. Jensen; Haiyan Cui; Bernard W. Futscher; Jesse D. Martinez

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
339 KB
Volume
50
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The 14‐3‐3 proteins are a set of seven highly conserved proteins that have recently been implicated in having a role in human tumorigenesis. However, the mechanism by which 14‐3‐3 proteins may act in this capacity is not well understood. In this study, we examined the expression of one of the 14‐3‐3 family members, 14‐3‐3σ, since it was shown previously to be aberrantly altered in human tumors. Using quantitative rtPCR and immunohistochemistry, we found that the expression levels of 14‐3‐3σ were elevated in the majority of human non‐small cell lung cancers (NSCLC) we examined. Surprisingly, we found that the 14‐3‐3σ gene was hypomethylated in lung tumors relative to normal lung tissue suggesting that decreased DNA methylation resulted in increased expression of 14‐3‐3σ in NSCLC. We also determined the gene copy number for 14‐3‐3σ in tumor samples and found no significant correlation with elevated mRNA expression. And also no mutations were found in 14‐3‐3σ gene. Overall, our data suggest that misregulated expression of 14‐3‐3σ gene may be due to altered methylation status. © 2011 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Increased expression of the LGALS3 (Gale
Increased expression of the LGALS3 (Galectin 3) gene in human non–small-cell lung cancer
✍ Akinobu Yoshimura; Akihiko Gemma; Yoko Hosoya; Eriko Komaki; Yukio Hosomi; Tetsu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract Patients with lung cancer have a poor prognosis because of the high metastatic potential of the neoplasm. Therefore, identifying new molecular targets for anti‐metastatic therapy is very important. To identify novel key factors of tumor metastasis in lung cancer, we established the gene

Epigenetic silencing of the PRSS3 putati
Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer
✍ Carmen J. Marsit; Chinedu Okpukpara; Hadi Danaee; Karl T. Kelsey 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Abstract The serine protease family member __PRSS3__ (__trypsinogen‐IV__) has been implicated as a putative tumor suppressor gene due to its loss of expression, which is correlated with promoter hypermethylation, in esophageal squamous cell carcinoma and gastric adenocarcinoma. As epigenetic alt

Expression of the major vault protein LR
Expression of the major vault protein LRP in human non-small-cell lung cancer cells: Activation by short-term exposure to antineoplastic drugs
✍ Walter Berger; Leonilla Elbling; Michael Micksche 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 419 KB 👁 2 views

Non-small-cell lung cancer (NSCLC) cells are characterised by resistance to the toxic impact of antineoplastic drugs both in vivo and in vitro. The lung resistance-related protein (LRP), identical with the human major vault protein, is over-expressed in a variety of tumour cells characterised by int

Expression of E1AF/PEA3, an Ets-related
Expression of E1AF/PEA3, an Ets-related transcription factor in human non-small-cell lung cancers: Its relevance in cell motility and invasion
✍ Hiromitsu Hiroumi; Hirotoshi Dosaka-Akita; Koichi Yoshida; Masanobu Shindoh; Tos 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 342 KB

Cell invasion and metastasis characterize the malignant potential of non-small-cell lung cancers (NSCLCs). We have previously reported that E1AF, a member of the Ets-related transcription factor family, confers invasive phenotype on breast cancer and oral squamous-cell carcinoma cell lines. In our s

Enhanced cytotoxicity induced by gefitin
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells
✍ Maarten L. Janmaat; José A. Rodriguez; Mariëlle Gallegos-Ruiz; Frank A.E. Kruyt; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 371 KB

## Abstract In this study, we have characterized a panel of NSCLC cell lines with differential sensitivity to gefitinib for activating mutations in __egfr__, __pik3ca__, and __k‐ras__, and basal protein expression levels of PTEN. The __egfr__ mutant NSCLC cell line H1650 as well as the __egfr__ wil